Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Patients with a cardiomyopathy.
- Who it may be relevant to
- Registry conditions: Hypertrophic, Ischemic, Restrictive Cardiomyopathy, Dilated Cardiomyopathies. Basic parameters: 18 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in each type of cardiomyopathy.
Detailed description
Coronary artery imaging techniques have taken a central role in the assessment of cardiovascular (CV) diagnosis over the past two decades. Many patients with a cardiomyopathy are also found to have a bystander coronary artery disease, not responsible for their cardiomyopathy. However, the prognostic value of those bystander coronary artery diseases is not known.
Also, new imaging techniques have been developed to assess coronary microvascular disease, but the prognostic value of these findings is not known.
In this study, the investigators evaluate the incidence and the prognosis of bystander coronary artery disease and microvascular disease in patients with ischemic, hypertrophic, dilated and restrictive cardiomyopathies in 5 French centers.
Coronary angiography, cardiac magnetic resonance (CMR), tomographic coronary artery angiography, single-photon emission computed tomography (SPECT), rest and stress trans-thoracic echocardiography (TTE) results will be recorded.
Macrovascular coronary artery disease is defined by :
* a stenosis \> 50 % in coronary angiography confirmed with myocardial ischemia (SPECT, stress echocardiography), * a stenosis \> 70 % (50% if it is the left main coronary artery) * or a stenosis 30-70 % with a fractional flow reserve (FFR) \< 0.8 Microvascular disease is defined by an index of microvascular resistance (IMR) \>23 or myocardial perfusion heterogeneity imaging (MPHI) \> 4 using SPECT or CMR.
Major adverse cardiovascular events (MACE) will be assessed 1 year, 2 years and 5 years after enrollment.
Interventions
- Other Patients with a cardiomyopathy
Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
Primary outcome measures
- Major Adverse Cardiovascular Events [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Ischemic
- Dilated
- Hypertrophic
- Restrictive cardiomyopathy.
Exclusion criteria
- Pregnant women
- Breastfeeding women
- Patients under legal protection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- University Hospital Grenoble — La Tronche
Identifiers
NCT: NCT03479580 · 38RC17.215 · 2017-A02064-49